Groundbreaking study explores enhanced immune response against SARS-CoV-2 variants post-vaccination.
The results of a study conducted by Oregon Health & Science University and published in the journal Emerging Infectious Diseases point to the need to routinely get updated vaccines, particularly for older individuals and those with underlying medical issues.
The virus is still circulating, it’s continuing to evolve, and it remains dangerous. Sooner or later, there will be another variant that evades the immunity we have already built up. Our study demonstrates that it’s worthwhile to update our immune repertoire.”- Fikadu Tafesse, Ph.D., co-senior author, associate professor of molecular microbiology and immunology, OHSU School of Medicine
Based on federal data, vaccination uptake has decreased in the United States as the epidemic has become less visible to the general population.
In the most recent trial, blood samples from 55 individuals were separated both before and after they got an improved vaccine starting last fall that targets the virus’s XBB.1.5 subvariant, which is part of the omicron variant.
In terms of the amount of antibodies produced and their capacity to neutralize both the original strain of SARS-CoV-2 and other variants that have arisen after the novel coronavirus arrived in late 2019, they discovered a robust response. Crucially, it seemed that the vaccination produced a robust defense against the JN.1 variety that is currently circulating widely around the globe, indicating that frequent vaccine updates will help combat new variants.
The findings represent yet another milestone in the SARS-CoV-2 virus’s development.
“Overall, this work strongly supports the use of the updated vaccine,” said co-senior author Marcel Curlin, M.D., associate professor of medicine (infectious diseases) in the OHSU School of Medicine and medical director of OHSU Occupational Health. “In the big picture, COVID-19 is not going away but lining up alongside the other common respiratory illnesses such as flu and RSV, which cause relatively mild disease for most people and a lot of harm to a few.”
OHSU was among the first, in contrast to most other research investigations, to evaluate if blood serum antibodies produced by vaccination might prevent the infection of a live virus in a biosafety level 3 laboratory.
Xammy Huu Nguyenla, Mastura Wahedi, Timothy Bates, and Mila Trank-Greene from OHSU are co-authors with Tafesse and Curlin.
more recommended stories
CTNNB1 Syndrome Study Explores Beta-Catenin DefectsKey Takeaways Researchers in Spain are.
Tuberculosis Breakthrough with Experimental AntibioticsKey Takeaways Experimental antibiotics disrupt a.
National Healthy Longevity Trial Receives Federal SupportKey Summary Up to $38 million.
Red Blood Cells Improve Glucose Tolerance Under HypoxiaKey Takeaways for Clinicians Chronic hypoxia.
Nanoplastics in Brain Tissue and Neurological RiskKey Takeaways for HCPs Nanoplastics are.
AI Predicts Chronic GVHD Risk After Stem Cell TransplantKey Takeaways A new AI-driven tool,.
Red Meat Consumption Linked to Higher Diabetes OddsKey Takeaways Higher intake of total,.
Pediatric Crohn’s Disease Microbial Signature IdentifiedKey Points at a Glance NYU.
Nanovaccine Design Boosts Immune Attack on HPV TumorsKey Highlights Reconfiguring peptide orientation significantly.
High-Fat Diets Cause Damage to Metabolic HealthKey Points Takeaways High-fat and ketogenic.
Leave a Comment